Brief: Orexo Q3 EBITDA Loss At SEK 47.4 Mln

Orexo AB

03/11/2021 07:23

Nov 3 (Reuters) - Orexo AB  ORX.ST :
    * OREXO Q3 2021 INTERIM REPORT
    * Q3 TOTAL NET REVENUES OF SEK 145.9 M (150.3)
    * Q3 NET LOSS OF -52.0 SEK M (-84.9)
    * Q3 EBITDA OF SEK -47.4 M (-20.9)
    * OUTLOOK 2021: DUE TO COVID-19 THE BUPRENORPHINE/NALOXONE
MARKET
WILL TEMPORARILY SHOW A LOWER ANNUAL GROWTH PACE AND REACH A
LEVEL OF 5-8 PERCENT
    * ZUBSOLV US NET SALES IN Q4 IS EXPECTED TO BE IN LINE WITH
Q3,
AND NET SALES FOR 2021 WILL DECLINE COMPARED TO 2020
    * OPEX FOR Q4 WILL BE IN LINE WITH Q3
    * OUTLOOK 2021: US PHARMA EBIT WILL EXCEED 50 PERCENT

Source text for Eikon:  ID:nWkr7s2t9W 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))